 | |
| Clinical data | |
|---|---|
| Trade names | Tybost |
| Other names | GS-9350 |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a616029 |
| License data |
|
| Drug class | CYP3A inhibitor [1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C40H53N7O5S2 |
| Molar mass | 776.03 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Cobicistat, sold under the brand name Tybost, is a medication used to treat HIV/AIDS. [1] It is often used to boost the effects of atazanavir or darunavir. [1] It is taken by mouth. [1] Additionally it is available as part of a number of combination medications. [3]
Common side effects include jaundice, nausea, and rash. [1] [2] Use is not recommended in pregnancy. [2] Use is not recommended in those with severe liver problems. [3] It has a number of important medication interactions. [2] It works by blocking the action of a group of liver enzymes called CYP3A; thereby slowing the breakdown of atazanavir or darunavir. [1]
Cobicistat was approved for medical use in the United States in 2012 and Europe in 2013. [2] [1] In the United Kingdom a month of medication costs the NHS about £21 as of 2021. [3] This amount in the United States costs about 270 USD. [4]
References
- ^ a b c d e f g h i j "Tybost". Archived from the original on 10 November 2021. Retrieved 6 January 2022.
- ^ a b c d e f "DailyMed - TYBOST- cobicistat tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 28 October 2020. Retrieved 5 January 2022.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 699. ISBN 978-0857114105.
- ^ "Cobicistat Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 6 January 2022.
|
| |
| Clinical data | |
|---|---|
| Trade names | Tybost |
| Other names | GS-9350 |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a616029 |
| License data |
|
| Drug class | CYP3A inhibitor [1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C40H53N7O5S2 |
| Molar mass | 776.03 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Cobicistat, sold under the brand name Tybost, is a medication used to treat HIV/AIDS. [1] It is often used to boost the effects of atazanavir or darunavir. [1] It is taken by mouth. [1] Additionally it is available as part of a number of combination medications. [3]
Common side effects include jaundice, nausea, and rash. [1] [2] Use is not recommended in pregnancy. [2] Use is not recommended in those with severe liver problems. [3] It has a number of important medication interactions. [2] It works by blocking the action of a group of liver enzymes called CYP3A; thereby slowing the breakdown of atazanavir or darunavir. [1]
Cobicistat was approved for medical use in the United States in 2012 and Europe in 2013. [2] [1] In the United Kingdom a month of medication costs the NHS about £21 as of 2021. [3] This amount in the United States costs about 270 USD. [4]
References
- ^ a b c d e f g h i j "Tybost". Archived from the original on 10 November 2021. Retrieved 6 January 2022.
- ^ a b c d e f "DailyMed - TYBOST- cobicistat tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 28 October 2020. Retrieved 5 January 2022.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 699. ISBN 978-0857114105.
- ^ "Cobicistat Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 6 January 2022.